Related Experiment Videos
Molecular cytogenetics in haematological malignancy: current technology and future prospects
Lyndal Kearney1, Sharon W Horsley
1Section of Haemato-Oncology, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. Lyndal.Kearney@icr.ac.uk
Chromosoma
|July 9, 2005
Summary
Cytogenetics and advanced molecular technologies like fluorescence in situ hybridisation (FISH) and gene expression profiling are crucial for diagnosing and understanding the pathogenesis of leukaemias and lymphomas.
Area of Science:
- Hematology
- Genetics
- Oncology
Background:
- Cytogenetics is vital for diagnosing hematological malignancies and identifying chromosomal rearrangements.
- Fluorescence in situ hybridisation (FISH) technologies revolutionized cytogenetics in the late 1980s.
- Microarray technologies have gained prominence more recently.
Purpose of the Study:
- To review the pivotal role of cytogenetics and emerging molecular technologies in hematological malignancy.
- To highlight advancements in diagnostic and pathogenetic insights for leukaemias and lymphomas.
Main Methods:
- Review of key cytogenetic techniques including fluorescence in situ hybridisation (FISH), multiplex-FISH (M-FISH, SKY), and comparative genomic hybridisation (CGH).
- Discussion of microarray technologies and gene expression profiling.
- Application of high-resolution array CGH in lymphoma research.
Main Results:
- FISH, M-FISH, SKY, and CGH have become significant tools in cytogenetics.
- Gene expression profiling shows promise as a future diagnostic alternative for acute leukaemias.
- High-resolution array CGH has identified new deletion and amplification regions in lymphomas.
Conclusions:
- Cytogenetic and molecular technologies are essential for advancing the understanding and diagnosis of hematological malignancies.
- Emerging technologies offer prospects for more precise diagnostics and targeted therapies for leukaemias and lymphomas.